Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cordlife Group ( (SG:P8A) ) has issued an announcement.
Cordlife Group Limited has issued a profit warning for the financial year ending 31 December 2024, anticipating a loss due to temporary suspension and conditional resumption of its operations in Singapore, as mandated by the Ministry of Health. Despite the renewal of its licences and full operational resumption from January 2025, the company faces uncertainty in its financial recovery and profitability for the year ending 2025.
More about Cordlife Group
Cordlife Group Limited, registered in Singapore, operates in the healthcare industry, focusing on cord blood and human tissue banking services. The company offers collection, processing, and storage services for cord blood and human tissues, with a key market presence in Singapore.
YTD Price Performance: 0.88%
Average Trading Volume: 4,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $28.78M
For a thorough assessment of P8A stock, go to TipRanks’ Stock Analysis page.
